ClinicalTrials.gg

Program

asimadoline

Also written as “Asimadoline”.

Its studies are mostly in Hot Flashes · Pruritus · Diarrhea · Ileus · Irritable Bowel Syndrome, led by Tioga Pharmaceuticals.

Furthest: phase 3, since Apr 6, 20106 company-led studies, 1 open or runningNext primary completion: Oct 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tioga Pharmaceuticals61 open or runningphase 3since Apr 6, 2010Feb 27, 2007Oct 31, 2027phase 2 · NCT07042516

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 27, 2007First study: phase 2 study in Post-Operative IleusFirst studyNCT00443040 · 35 enrolled · United States
  2. Mar 29, 2007Phase 2 study in Irritable Bowel SyndromeNCT00454688 · 596 enrolled · United States
  3. Apr 6, 2010Phase 3 study in Diarrhea Predominant Irritable Bowel SyndromeNCT01100684 · 611 enrolled · United States
  4. Jun 13, 2011Phase 1 study in HealthyNCT01380561 · 6 enrolled · United States
  5. Feb 10, 2015Phase 2 study in PruritusNCT02475447 · 249 enrolled · United States
  6. Jun 19, 2025Phase 2 study in Hot FlashesNCT07042516 · 120 planned · United States

Ahead

  1. Oct 31, 2027Primary completion: phase 2 study in Hot FlashesNCT07042516

TargetBeta

OPRK1 →read by rule
“Kappa opioid receptor agonist”ChEMBL 37, by rule

Other programs on OPRK1

ProgramCompanyFurthest phaseStudies
Naltrexoneruleorexigen-therapeutics-incphase 442
nalmefeneruleH. Lundbeckphase 420
NalbuphineruleTrevi Therapeuticsphase 420
cebranopadolruleTris Pharmaphase 318
AticaprantruleJohnson & Johnsonphase 313
nalfurafineruletoray-industries-incphase 39
icalcaprantAbbViephase 26

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07042516Hot Flashes · United States2RecruitingOct 31, 2027120
NCT02475447Pruritus · United States2CompletedJun 2017249
NCT01380561Healthy · United States1CompletedJul 20116
NCT01100684Diarrhea Predominant Irritable Bowel Syndrome · United States3CompletedJun 2013611
NCT00454688Irritable Bowel Syndrome · United States2CompletedNov 2007596
NCT00443040Post-Operative Ileus · United States2TerminatedFeb 200835

How it is read

Names in the registry

  • “Asimadoline”, 5 entries
  • “asimadoline”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.